Last reviewed · How we verify
placebo to match pioglitazone
placebo to match pioglitazone is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials of pioglitazone.
This is an inert placebo formulated to match the appearance and administration of pioglitazone, a thiazolidinedione insulin sensitizer.
This is an inert placebo formulated to match the appearance and administration of pioglitazone, a thiazolidinedione insulin sensitizer. Used for Control arm in Phase 3 clinical trials of pioglitazone.
At a glance
| Generic name | placebo to match pioglitazone |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Placebos are inactive substances used as controls in clinical trials to measure the true efficacy of an active drug by comparison. This particular placebo is designed to be indistinguishable from pioglitazone in Phase 3 trials, allowing for blinded assessment of pioglitazone's effects on insulin sensitivity and glucose metabolism in diabetes patients.
Approved indications
- Control arm in Phase 3 clinical trials of pioglitazone
Common side effects
Key clinical trials
- Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration? (PHASE4)
- Bioenergetic Effect of Pioglitazone in CLD-PH (PHASE2)
- The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans (PHASE4)
- Acetazolamide Add-On Therapy to OSA Surgery (PHASE4)
- Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA) (PHASE1)
- Polycystic Ovary Syndrome (PCOS) and Sleep Apnea (PHASE4)
- Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases (PHASE4)
- Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- placebo to match pioglitazone CI brief — competitive landscape report
- placebo to match pioglitazone updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about placebo to match pioglitazone
What is placebo to match pioglitazone?
How does placebo to match pioglitazone work?
What is placebo to match pioglitazone used for?
Who makes placebo to match pioglitazone?
What development phase is placebo to match pioglitazone in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Control arm in Phase 3 clinical trials of pioglitazone
- Compare: placebo to match pioglitazone vs similar drugs
- Pricing: placebo to match pioglitazone cost, discount & access